Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $31.4 million.

  • Immunome's Total Current Liabilities fell 2044.88% to $31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 2044.88%. This contributed to the annual value of $54.3 million for FY2024, which is 14878.37% up from last year.
  • As of Q3 2025, Immunome's Total Current Liabilities stood at $31.4 million, which was down 2044.88% from $22.9 million recorded in Q2 2025.
  • Immunome's Total Current Liabilities' 5-year high stood at $54.3 million during Q4 2024, with a 5-year trough of $21.8 million in Q4 2023.
  • In the last 3 years, Immunome's Total Current Liabilities had a median value of $30.8 million in 2024 and averaged $31.4 million.
  • As far as peak fluctuations go, Immunome's Total Current Liabilities skyrocketed by 14878.37% in 2024, and later crashed by 4266.17% in 2025.
  • Immunome's Total Current Liabilities (Quarter) stood at $21.8 million in 2023, then soared by 148.78% to $54.3 million in 2024, then tumbled by 42.1% to $31.4 million in 2025.
  • Its Total Current Liabilities stands at $31.4 million for Q3 2025, versus $22.9 million for Q2 2025 and $30.8 million for Q1 2025.